Global Primary Sclerosing Cholangitis (PSC) Market Growth (Status and Outlook) 2026-2032
The global Primary Sclerosing Cholangitis (PSC) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term 'sclerosing' refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
LPI (LP Information)' newest research report, the “Primary Sclerosing Cholangitis (PSC) Industry Forecast” looks at past sales and reviews total world Primary Sclerosing Cholangitis (PSC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Primary Sclerosing Cholangitis (PSC) sales for 2026 through 2032. With Primary Sclerosing Cholangitis (PSC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Sclerosing Cholangitis (PSC) industry.
This Insight Report provides a comprehensive analysis of the global Primary Sclerosing Cholangitis (PSC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Primary Sclerosing Cholangitis (PSC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Sclerosing Cholangitis (PSC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Sclerosing Cholangitis (PSC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Sclerosing Cholangitis (PSC).
This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis (PSC) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term 'sclerosing' refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
LPI (LP Information)' newest research report, the “Primary Sclerosing Cholangitis (PSC) Industry Forecast” looks at past sales and reviews total world Primary Sclerosing Cholangitis (PSC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Primary Sclerosing Cholangitis (PSC) sales for 2026 through 2032. With Primary Sclerosing Cholangitis (PSC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Sclerosing Cholangitis (PSC) industry.
This Insight Report provides a comprehensive analysis of the global Primary Sclerosing Cholangitis (PSC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Primary Sclerosing Cholangitis (PSC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Sclerosing Cholangitis (PSC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Sclerosing Cholangitis (PSC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Sclerosing Cholangitis (PSC).
This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis (PSC) market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Medical Treatement
- Liver Transplantation
- Others
- Hospital
- Clinics
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Acorda Therapeutics
- Gilead Sciences
- NGM Biopharmaceuticals
- Intercept Pharmaceuticals
- Dr. Falk Pharma
- Allergan
- Shire
- Durect Corporation
- Conatus Pharmaceuticals
- Sirnaomics
- Shenzhen HighTide Biopharmaceutical
- Glenmark
- Impax Laboratories
- Mylan
- Teva Pharmaceuticals
- Daewoong Pharmaceutical
- Mitsubishi Tanabe Pharma
- Lannett
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size (2021-2032)
2.1.2 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Primary Sclerosing Cholangitis (PSC) by Country/Region (2021, 2025 & 2032)
2.2 Primary Sclerosing Cholangitis (PSC) Segment by Type
2.2.1 Medical Treatement
2.2.2 Liver Transplantation
2.2.3 Others
2.2.4 Primary Sclerosing Cholangitis (PSC) Market Size by Type
2.2.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
2.3 Primary Sclerosing Cholangitis (PSC) Segment by Application
2.3.1 Hospital
2.3.2 Clinics
2.3.3 Others
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Size by Application
2.3.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SIZE BY PLAYER
3.1 Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Player
3.1.1 Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)
3.2 Global Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) BY REGION
4.1 Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)
4.2 Global Primary Sclerosing Cholangitis (PSC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.4 APAC Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.5 Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.6 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)
5.2 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
5.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)
6.2 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
6.3 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) by Region (2021-2026)
8.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
8.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST
10.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.1.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.1.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast
10.1.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast
10.1.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast
10.1.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast
10.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
10.2.1 United States Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.2 Canada Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.3 Mexico Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.4 Brazil Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.3.1 China Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.2 Japan Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.3 Korea Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.4 Southeast Asia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.5 India Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.6 Australia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
10.4.1 Germany Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.2 France Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.3 UK Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.4 Italy Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.5 Russia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.5.1 Egypt Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.2 South Africa Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.3 Israel Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.4 Turkey Market Primary Sclerosing Cholangitis (PSC) Forecast
10.6 Global Primary Sclerosing Cholangitis (PSC) Forecast by Type (2027-2032)
10.7 Global Primary Sclerosing Cholangitis (PSC) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Primary Sclerosing Cholangitis (PSC) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Information
11.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Acorda Therapeutics Main Business Overview
11.1.5 Acorda Therapeutics Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Information
11.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 NGM Biopharmaceuticals Main Business Overview
11.3.5 NGM Biopharmaceuticals Latest Developments
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Information
11.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Intercept Pharmaceuticals Main Business Overview
11.4.5 Intercept Pharmaceuticals Latest Developments
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Information
11.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Dr. Falk Pharma Main Business Overview
11.5.5 Dr. Falk Pharma Latest Developments
11.6 Allergan
11.6.1 Allergan Company Information
11.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Allergan Main Business Overview
11.6.5 Allergan Latest Developments
11.7 Shire
11.7.1 Shire Company Information
11.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Offered
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Shire Main Business Overview
11.7.5 Shire Latest Developments
11.8 Durect Corporation
11.8.1 Durect Corporation Company Information
11.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Durect Corporation Main Business Overview
11.8.5 Durect Corporation Latest Developments
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Information
11.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Conatus Pharmaceuticals Main Business Overview
11.9.5 Conatus Pharmaceuticals Latest Developments
11.10 Sirnaomics
11.10.1 Sirnaomics Company Information
11.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Sirnaomics Main Business Overview
11.10.5 Sirnaomics Latest Developments
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Information
11.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Shenzhen HighTide Biopharmaceutical Main Business Overview
11.11.5 Shenzhen HighTide Biopharmaceutical Latest Developments
11.12 Glenmark
11.12.1 Glenmark Company Information
11.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Glenmark Main Business Overview
11.12.5 Glenmark Latest Developments
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Information
11.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Impax Laboratories Main Business Overview
11.13.5 Impax Laboratories Latest Developments
11.14 Mylan
11.14.1 Mylan Company Information
11.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Offered
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Mylan Main Business Overview
11.14.5 Mylan Latest Developments
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Information
11.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Teva Pharmaceuticals Main Business Overview
11.15.5 Teva Pharmaceuticals Latest Developments
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Information
11.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Daewoong Pharmaceutical Main Business Overview
11.16.5 Daewoong Pharmaceutical Latest Developments
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Information
11.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Mitsubishi Tanabe Pharma Main Business Overview
11.17.5 Mitsubishi Tanabe Pharma Latest Developments
11.18 Lannett
11.18.1 Lannett Company Information
11.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Offered
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Lannett Main Business Overview
11.18.5 Lannett Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (PSC) Market Size (2021-2032)
2.1.2 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Primary Sclerosing Cholangitis (PSC) by Country/Region (2021, 2025 & 2032)
2.2 Primary Sclerosing Cholangitis (PSC) Segment by Type
2.2.1 Medical Treatement
2.2.2 Liver Transplantation
2.2.3 Others
2.2.4 Primary Sclerosing Cholangitis (PSC) Market Size by Type
2.2.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
2.3 Primary Sclerosing Cholangitis (PSC) Segment by Application
2.3.1 Hospital
2.3.2 Clinics
2.3.3 Others
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Size by Application
2.3.4.1 Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SIZE BY PLAYER
3.1 Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Player
3.1.1 Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)
3.2 Global Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) BY REGION
4.1 Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)
4.2 Global Primary Sclerosing Cholangitis (PSC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.4 APAC Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.5 Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
4.6 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)
5.2 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
5.3 Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026)
6.2 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
6.3 APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) by Region (2021-2026)
8.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026)
8.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST
10.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.1.1 Global Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.1.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast
10.1.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast
10.1.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast
10.1.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast
10.2 Americas Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
10.2.1 United States Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.2 Canada Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.3 Mexico Market Primary Sclerosing Cholangitis (PSC) Forecast
10.2.4 Brazil Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3 APAC Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.3.1 China Primary Sclerosing Cholangitis (PSC) Market Forecast
10.3.2 Japan Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.3 Korea Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.4 Southeast Asia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.5 India Market Primary Sclerosing Cholangitis (PSC) Forecast
10.3.6 Australia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4 Europe Primary Sclerosing Cholangitis (PSC) Forecast by Country (2027-2032)
10.4.1 Germany Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.2 France Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.3 UK Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.4 Italy Market Primary Sclerosing Cholangitis (PSC) Forecast
10.4.5 Russia Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Forecast by Region (2027-2032)
10.5.1 Egypt Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.2 South Africa Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.3 Israel Market Primary Sclerosing Cholangitis (PSC) Forecast
10.5.4 Turkey Market Primary Sclerosing Cholangitis (PSC) Forecast
10.6 Global Primary Sclerosing Cholangitis (PSC) Forecast by Type (2027-2032)
10.7 Global Primary Sclerosing Cholangitis (PSC) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Primary Sclerosing Cholangitis (PSC) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Information
11.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Acorda Therapeutics Main Business Overview
11.1.5 Acorda Therapeutics Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Information
11.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 NGM Biopharmaceuticals Main Business Overview
11.3.5 NGM Biopharmaceuticals Latest Developments
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Information
11.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Intercept Pharmaceuticals Main Business Overview
11.4.5 Intercept Pharmaceuticals Latest Developments
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Information
11.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Dr. Falk Pharma Main Business Overview
11.5.5 Dr. Falk Pharma Latest Developments
11.6 Allergan
11.6.1 Allergan Company Information
11.6.2 Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Allergan Main Business Overview
11.6.5 Allergan Latest Developments
11.7 Shire
11.7.1 Shire Company Information
11.7.2 Shire Primary Sclerosing Cholangitis (PSC) Product Offered
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Shire Main Business Overview
11.7.5 Shire Latest Developments
11.8 Durect Corporation
11.8.1 Durect Corporation Company Information
11.8.2 Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Durect Corporation Main Business Overview
11.8.5 Durect Corporation Latest Developments
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Information
11.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Conatus Pharmaceuticals Main Business Overview
11.9.5 Conatus Pharmaceuticals Latest Developments
11.10 Sirnaomics
11.10.1 Sirnaomics Company Information
11.10.2 Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Sirnaomics Main Business Overview
11.10.5 Sirnaomics Latest Developments
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Information
11.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Shenzhen HighTide Biopharmaceutical Main Business Overview
11.11.5 Shenzhen HighTide Biopharmaceutical Latest Developments
11.12 Glenmark
11.12.1 Glenmark Company Information
11.12.2 Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Glenmark Main Business Overview
11.12.5 Glenmark Latest Developments
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Information
11.13.2 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Impax Laboratories Main Business Overview
11.13.5 Impax Laboratories Latest Developments
11.14 Mylan
11.14.1 Mylan Company Information
11.14.2 Mylan Primary Sclerosing Cholangitis (PSC) Product Offered
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Mylan Main Business Overview
11.14.5 Mylan Latest Developments
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Information
11.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Teva Pharmaceuticals Main Business Overview
11.15.5 Teva Pharmaceuticals Latest Developments
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Information
11.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Daewoong Pharmaceutical Main Business Overview
11.16.5 Daewoong Pharmaceutical Latest Developments
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Information
11.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Mitsubishi Tanabe Pharma Main Business Overview
11.17.5 Mitsubishi Tanabe Pharma Latest Developments
11.18 Lannett
11.18.1 Lannett Company Information
11.18.2 Lannett Primary Sclerosing Cholangitis (PSC) Product Offered
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Lannett Main Business Overview
11.18.5 Lannett Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Primary Sclerosing Cholangitis (PSC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Medical Treatement
Table 4. Major Players of Liver Transplantation
Table 5. Major Players of Others
Table 6. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Table 9. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Table 12. Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)
Table 14. Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
Table 15. Primary Sclerosing Cholangitis (PSC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Table 20. Global Primary Sclerosing Cholangitis (PSC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)
Table 24. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Table 26. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Table 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Table 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)
Table 34. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis (PSC)
Table 40. Key Market Challenges & Risks of Primary Sclerosing Cholangitis (PSC)
Table 41. Key Industry Trends of Primary Sclerosing Cholangitis (PSC)
Table 42. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 47. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
Table 48. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Acorda Therapeutics Main Business
Table 50. Acorda Therapeutics Latest Developments
Table 51. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 52. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
Table 53. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Gilead Sciences Main Business
Table 55. Gilead Sciences Latest Developments
Table 56. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 57. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 58. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. NGM Biopharmaceuticals Main Business
Table 60. NGM Biopharmaceuticals Latest Developments
Table 61. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 62. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 63. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Intercept Pharmaceuticals Main Business
Table 65. Intercept Pharmaceuticals Latest Developments
Table 66. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 67. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
Table 68. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Dr. Falk Pharma Main Business
Table 70. Dr. Falk Pharma Latest Developments
Table 71. Allergan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 72. Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
Table 73. Allergan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Allergan Main Business
Table 75. Allergan Latest Developments
Table 76. Shire Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 77. Shire Primary Sclerosing Cholangitis (PSC) Product Offered
Table 78. Shire Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Shire Main Business
Table 80. Shire Latest Developments
Table 81. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 82. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
Table 83. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Durect Corporation Main Business
Table 85. Durect Corporation Latest Developments
Table 86. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 87. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 88. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Conatus Pharmaceuticals Main Business
Table 90. Conatus Pharmaceuticals Latest Developments
Table 91. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 92. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
Table 93. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Sirnaomics Main Business
Table 95. Sirnaomics Latest Developments
Table 96. Shenzhen HighTide Biopharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 97. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
Table 98. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Shenzhen HighTide Biopharmaceutical Main Business
Table 100. Shenzhen HighTide Biopharmaceutical Latest Developments
Table 101. Glenmark Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 102. Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered
Table 103. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Glenmark Main Business
Table 105. Glenmark Latest Developments
Table 106. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 107. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered
Table 108. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Impax Laboratories Main Business
Table 110. Impax Laboratories Latest Developments
Table 111. Mylan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 112. Mylan Primary Sclerosing Cholangitis (PSC) Product Offered
Table 113. Mylan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Mylan Main Business
Table 115. Mylan Latest Developments
Table 116. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 117. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 118. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Teva Pharmaceuticals Main Business
Table 120. Teva Pharmaceuticals Latest Developments
Table 121. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 122. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
Table 123. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Daewoong Pharmaceutical Main Business
Table 125. Daewoong Pharmaceutical Latest Developments
Table 126. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 127. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
Table 128. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Mitsubishi Tanabe Pharma Main Business
Table 130. Mitsubishi Tanabe Pharma Latest Developments
Table 131. Lannett Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 132. Lannett Primary Sclerosing Cholangitis (PSC) Product Offered
Table 133. Lannett Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Lannett Main Business
Table 135. Lannett Latest Developments
Table 1. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Primary Sclerosing Cholangitis (PSC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Medical Treatement
Table 4. Major Players of Liver Transplantation
Table 5. Major Players of Others
Table 6. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Table 9. Primary Sclerosing Cholangitis (PSC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Table 12. Global Primary Sclerosing Cholangitis (PSC) Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player (2021-2026)
Table 14. Primary Sclerosing Cholangitis (PSC) Key Players Head office and Products Offered
Table 15. Primary Sclerosing Cholangitis (PSC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Table 20. Global Primary Sclerosing Cholangitis (PSC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)
Table 24. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Table 26. Americas Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Table 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Table 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country (2021-2026)
Table 34. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis (PSC)
Table 40. Key Market Challenges & Risks of Primary Sclerosing Cholangitis (PSC)
Table 41. Key Industry Trends of Primary Sclerosing Cholangitis (PSC)
Table 42. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Primary Sclerosing Cholangitis (PSC) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 47. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offered
Table 48. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Acorda Therapeutics Main Business
Table 50. Acorda Therapeutics Latest Developments
Table 51. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 52. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offered
Table 53. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Gilead Sciences Main Business
Table 55. Gilead Sciences Latest Developments
Table 56. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 57. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 58. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. NGM Biopharmaceuticals Main Business
Table 60. NGM Biopharmaceuticals Latest Developments
Table 61. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 62. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 63. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Intercept Pharmaceuticals Main Business
Table 65. Intercept Pharmaceuticals Latest Developments
Table 66. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 67. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
Table 68. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Dr. Falk Pharma Main Business
Table 70. Dr. Falk Pharma Latest Developments
Table 71. Allergan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 72. Allergan Primary Sclerosing Cholangitis (PSC) Product Offered
Table 73. Allergan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Allergan Main Business
Table 75. Allergan Latest Developments
Table 76. Shire Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 77. Shire Primary Sclerosing Cholangitis (PSC) Product Offered
Table 78. Shire Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Shire Main Business
Table 80. Shire Latest Developments
Table 81. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 82. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offered
Table 83. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Durect Corporation Main Business
Table 85. Durect Corporation Latest Developments
Table 86. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 87. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 88. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Conatus Pharmaceuticals Main Business
Table 90. Conatus Pharmaceuticals Latest Developments
Table 91. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 92. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offered
Table 93. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Sirnaomics Main Business
Table 95. Sirnaomics Latest Developments
Table 96. Shenzhen HighTide Biopharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 97. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
Table 98. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Shenzhen HighTide Biopharmaceutical Main Business
Table 100. Shenzhen HighTide Biopharmaceutical Latest Developments
Table 101. Glenmark Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 102. Glenmark Primary Sclerosing Cholangitis (PSC) Product Offered
Table 103. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Glenmark Main Business
Table 105. Glenmark Latest Developments
Table 106. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 107. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offered
Table 108. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Impax Laboratories Main Business
Table 110. Impax Laboratories Latest Developments
Table 111. Mylan Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 112. Mylan Primary Sclerosing Cholangitis (PSC) Product Offered
Table 113. Mylan Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Mylan Main Business
Table 115. Mylan Latest Developments
Table 116. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 117. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offered
Table 118. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Teva Pharmaceuticals Main Business
Table 120. Teva Pharmaceuticals Latest Developments
Table 121. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 122. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offered
Table 123. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Daewoong Pharmaceutical Main Business
Table 125. Daewoong Pharmaceutical Latest Developments
Table 126. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 127. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offered
Table 128. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Mitsubishi Tanabe Pharma Main Business
Table 130. Mitsubishi Tanabe Pharma Latest Developments
Table 131. Lannett Details, Company Type, Primary Sclerosing Cholangitis (PSC) Area Served and Its Competitors
Table 132. Lannett Primary Sclerosing Cholangitis (PSC) Product Offered
Table 133. Lannett Primary Sclerosing Cholangitis (PSC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Lannett Main Business
Table 135. Lannett Latest Developments
LIST OF FIGURES
Figure 1. Primary Sclerosing Cholangitis (PSC) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Primary Sclerosing Cholangitis (PSC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2025)
Figure 8. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type in 2025
Figure 10. Primary Sclerosing Cholangitis (PSC) in Hospital
Figure 11. Global Primary Sclerosing Cholangitis (PSC) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Primary Sclerosing Cholangitis (PSC) in Clinics
Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market: Clinics (2021-2026) & ($ millions)
Figure 14. Primary Sclerosing Cholangitis (PSC) in Others
Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market: Others (2021-2026) & ($ millions)
Figure 16. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application in 2025
Figure 17. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player in 2025
Figure 18. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 20. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 21. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 23. Americas Primary Sclerosing Cholangitis (PSC) Value Market Share by Country in 2025
Figure 24. United States Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region in 2025
Figure 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 31. China Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country in 2025
Figure 38. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 54. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 55. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 57. United States Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 58. Canada Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 61. China Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 62. Japan Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 63. Korea Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 65. India Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 66. Australia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 67. Germany Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 68. France Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 69. UK Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 70. Italy Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 71. Russia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 74. Israel Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 76. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 1. Primary Sclerosing Cholangitis (PSC) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Primary Sclerosing Cholangitis (PSC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2025)
Figure 8. Primary Sclerosing Cholangitis (PSC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type in 2025
Figure 10. Primary Sclerosing Cholangitis (PSC) in Hospital
Figure 11. Global Primary Sclerosing Cholangitis (PSC) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Primary Sclerosing Cholangitis (PSC) in Clinics
Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market: Clinics (2021-2026) & ($ millions)
Figure 14. Primary Sclerosing Cholangitis (PSC) in Others
Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market: Others (2021-2026) & ($ millions)
Figure 16. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application in 2025
Figure 17. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Player in 2025
Figure 18. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 20. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 21. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2021-2026 ($ millions)
Figure 23. Americas Primary Sclerosing Cholangitis (PSC) Value Market Share by Country in 2025
Figure 24. United States Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region in 2025
Figure 29. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 31. China Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Country in 2025
Figure 38. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 54. APAC Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 55. Europe Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 57. United States Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 58. Canada Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 61. China Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 62. Japan Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 63. Korea Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 65. India Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 66. Australia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 67. Germany Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 68. France Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 69. UK Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 70. Italy Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 71. Russia Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 74. Israel Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
Figure 76. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Primary Sclerosing Cholangitis (PSC) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Primary Sclerosing Cholangitis (PSC) Market Size 2027-2032 ($ millions)
